Fulvest 250 mg (Fulvestrant) Injection – Advanced Breast Cancer Therapy by Eskayef Pharmaceuticals
Fulvest 250 mg (Fulvestrant) Injection is a powerful estrogen receptor antagonist used in the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer. Manufactured by Eskayef Pharmaceuticals Ltd.—a globally recognized pharmaceutical company—and distributed by Saif Pharma, this medication is designed specifically for postmenopausal women either as a monotherapy or in combination with CDK4/6 inhibitors like ribociclib, palbociclib, or abemaciclib. With its high potency and clinical effectiveness, Fulvest 250 mg is an essential therapy in oncology care worldwide.
Indications
Fulvest 250 mg (Fulvestrant) Injection is indicated for:
HR-positive, HER2-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy.
HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.
In combination with ribociclib, for initial endocrine-based treatment or after disease progression.
In combination with palbociclib or abemaciclib, for patients with disease progression after prior endocrine therapy.
Pharmacology & Mechanism of Action
Fulvestrant is a selective estrogen receptor degrader (SERD) that works by competitively binding to estrogen receptors (ER) and causing their degradation. This blocks the estrogen-mediated signaling pathways responsible for the growth of HR-positive breast tumors.
In vitro studies have shown that fulvestrant effectively inhibits both tamoxifen-resistant and estrogen-sensitive breast cancer cells, while in vivo models confirmed its ability to delay tumor establishment and inhibit growth of established tumors.
Unlike other hormone therapies, fulvestrant does not exhibit agonist activity, making it a pure antiestrogen agent—an essential quality for managing hormone-sensitive cancers.
Dosage & Administration
Standard Dose: 500 mg via intramuscular injection administered into each buttock (gluteal muscle) slowly over 1–2 minutes on Days 1, 15, 29, and once monthly thereafter.
Patients with Moderate Hepatic Impairment: 250 mg administered as a single 5 mL injection following the same schedule.
Pediatric Use: Safety and efficacy have not been established in pediatric populations.
Drug Interactions
No significant drug-drug interactions have been identified. Though fulvestrant is metabolized by the CYP3A4 enzyme, co-administration with CYP3A4 inhibitors (like ketoconazole) or inducers (like rifampin) does not require dose adjustment. This makes Fulvest 250 mg a convenient option for patients with complex treatment regimens.
Side Effects
Common adverse reactions (≥5% incidence) include:
Injection site pain
Nausea and vomiting
Arthralgia and bone pain
Fatigue and headache
Hot flashes and anorexia
Constipation and cough
Elevated liver enzymes (ALT, AST, ALP) in over 15% of patients
Although these side effects are usually manageable, patients should be closely monitored, especially if symptoms persist or worsen.
Pregnancy & Lactation
Fulvestrant can cause embryo-fetal toxicity. It is contraindicated during pregnancy, and women of reproductive age should be advised to use effective contraception. The presence of the drug in human milk is unknown, and breastfeeding is not recommended while undergoing treatment.
Warnings & Precautions
Risk of Bleeding: Use with caution in patients on anticoagulants or those with bleeding disorders.
Hepatic Impairment: Reduced dosing is essential to avoid elevated plasma concentrations.
Injection Site Caution: Avoid the sciatic nerve when injecting into the dorsogluteal area.
Estradiol Testing Interference: May cause falsely elevated estradiol levels during monitoring via immunoassays.
Overdose & Management
Data on overdose is limited. In healthy volunteers, fulvestrant plasma levels up to 10-15 times the therapeutic dose showed no severe toxicity. In the case of an overdose, supportive measures should be taken, with symptomatic treatment as necessary. There is no known antidote.
Therapeutic Class
Cytotoxic Chemotherapy – specifically a hormonal therapy option for hormone-sensitive breast cancer.
Storage Conditions
Store in a refrigerated environment (2°C–8°C). Keep the injection in its original carton to protect from light until time of use.
Manufacturer: Eskayef Pharmaceuticals Ltd.
With a legacy beginning in 1990, Eskayef Pharmaceuticals Ltd. has established itself as one of Bangladesh’s most trusted and advanced pharmaceutical manufacturers. Built upon the global heritage of SK&F, USA, and supported by the Transcom Group, Eskayef continues to deliver world-class medications trusted by healthcare providers in over 50 countries. Fulvest 250 mg stands as a testament to their commitment to quality, precision, and innovation in oncology treatment.
Supplier: Saif Pharma
Established in 2014, Saif Pharma is a professional oncology medicine supplier dedicated to delivering cost-effective and reliable cancer treatments to over 60 countries, including the United States, Canada, Saudi Arabia, UAE, China, and India. Saif Pharma focuses on accessibility, quality, and compassionate care—making effective cancer treatment available across borders.
Conclusion
Fulvest 250 mg (Fulvestrant) Injection is a vital treatment in the fight against HR-positive, HER2-negative breast cancer in postmenopausal women. Its proven effectiveness in monotherapy and in combination with CDK4/6 inhibitors, along with a manageable side effect profile, makes it a gold-standard option in advanced oncology care. Manufactured by Eskayef Pharmaceuticals Ltd. and supplied globally by Saif Pharma, Fulvest 250 mg continues to empower healthcare professionals and patients in the ongoing battle against breast cancer.
